Advertisement

Topics

Remarkable Responses to Checkpoint Blockade in Solid Tumors of Many Types

20:00 EDT 28 Jun 2017 | NEJM

Fifty-three percent of patients with progressive disease responded to pembrolizumab.

Original Article: Remarkable Responses to Checkpoint Blockade in Solid Tumors of Many Types

NEXT ARTICLE

More From BioPortfolio on "Remarkable Responses to Checkpoint Blockade in Solid Tumors of Many Types"

Advertisement
Quick Search
Advertisement
Advertisement